Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

clarkhealthcommunications

- PMLiVE

Roche’s tiragolumab plus Tecentriq combo wins FDA breakthrough therapy designation

Swiss pharma is aiming for approval in first-line NSCLC

Biogen Idec building

New intramuscular administration for Biogen’s MS therapy Plegridy approved in the EU

New administration offers same efficacy as subcutaneous injection

- PMLiVE

WHO advises both doses of Pfizer/BioNTech’s COVID-19 vaccine within a 21-28 day schedule

Recommendations made by the WHO's Strategic Advisory Group of Experts on Immunization

- PMLiVE

Moderna could potentially deliver one billion COVID-19 vaccine doses this year

EMA committee has recommended authorisation of the vaccine in the EU

- PMLiVE

Putting theory into practice

Ideas about new product adoption are dangerously out of date

- PMLiVE

Cancer Research UK study finds different responses to COVID-19 among cancer patients

Some blood cancer patients took five times longer than average to recover from the virus

- PMLiVE

FDA will not alter dosing schedules for authorised COVID-19 vaccines

Time period between first and second vaccines has been extended in the UK

- PMLiVE

Inovio plans late-stage COVID-19 vaccine study in second quarter 2021

FDA had placed trial on a temporary hold in September 2020

- PMLiVE

Successful product commercialisation: what can we learn from the rare disease setting?

Achieving launch success in an increasingly challenging commercial environment

- PMLiVE

Pfizer/BioNTech to offer COVID-19 vaccine to placebo recipients

Only those trial participants who are currently eligible under the EUA will be offered the vaccine

- PMLiVE

Sinopharm’s COVID-19 vaccine scores approval in China

Vaccine found to be 79% effective in top-line results

- PMLiVE

Pfizer, Sanofi and others set to increase US drug prices in 2021

Pressure from COVID-19 restrictions leads to drug price increases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links